Conversely, it has been demonstrated that the reactivation of p53/miR-34a/MYCN axis modulates the sensitivity to cisplatin in NSCLC [201], a chemotherapeutic commonly used for NB treatment. The gene discussed is TP53; the disease is neuroblastoma.